phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Key International Mpox Trial Finds No Clinical Benefit from Tecovirimat

William A. Fischer II, MD, Director of Emerging Pathogens at UNC's Institute for Global Health and Infectious Diseases and Joe Eron, MD, UNC Chief of Infectious Diseases and chair of the ACTG, co-authored a study that found tecovirimat used to treat mpox does not shorten time to lesion resolution, reduce pain, or speed viral clearance in adults. Published today in the New England Journal of Medicine, the results call for a renewed focus on new antivirals and combination strategies.

March 2, 2026


March 12 2026

March 11 2026

March 10 2026

March 9 2026

March 8 2026

March 7 2026

March 6 2026

March 5 2026

March 4 2026

March 3 2026

March 2 2026

March 1 2026

February 28 2026

February 27 2026

February 26 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy